Cancer treatment firm Sirtex Medical said the European Society of Medical Oncology (ESMO) has included the company's yttrium-90 (Y-90) microspheres as an option in new guidelines for the treatment of intrahepatic cholangiocarcinoma (iCCA).
Specifically, ESMO said selective internal radiation therapy (SIRT) using Y-90 microspheres may be considered as an option for postchemotherapy treatment of iCCA. The full ESMO biliary cancer treatment guidelines were published in September as a supplement to the Annals of Oncology.
